BioLife Solutions announced the execution of an agreement to supply its CryoStor cell freeze media and HypoThermosol cell storage and shipping media to Iovance Biotherapeutics. 

Iovance is currently conducting several clinical trials for tumor infiltrating lymphocyte (TIL) therapies targeting multiple solid tumor types including metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck and recurrent, metastatic or persistent cervical cancer.

Mike Rice, BioLife president and chief executive officer, said, “We are very pleased to support the team at Iovance in their mission to bring potentially lifesaving cancer therapies to the market. It’s very rewarding to see our proprietary biopreservation media products being broadly adopted in the regenerative medicine market, due to the improved yield and extended shelf life our IP platform can offer our customers.”

BioLife management estimates that CryoStor and HypoThermosol have been incorporated into the manufacturing processes of at least 250 regenerative medicine applications, including numerous late-stage clinical trials.